NYSEAMERICAN:CLDI

Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

Calidi Biotherapeutics logo
$0.60 -0.02 (-3.15%)
Closing price 11/16/2026 04:10 PM Eastern
Extended Trading
$0.61 +0.01 (+1.11%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Calidi Biotherapeutics Stock (NYSEAMERICAN:CLDI)

Advanced

Key Stats

Today's Range
$0.59
▼
$0.65
50-Day Range
$0.60
▼
$1.36
52-Week Range
$0.59
▼
$24.80
Volume
39,265 shs
Average Volume
46,353 shs
Market Capitalization
$1.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calidi Biotherapeutics is a clinical-stage biotechnology company developing cell-based therapies for cancer. Its approach uses stem cells as delivery vehicles for oncolytic viruses, which are designed to infect and destroy cancer cells and help activate the body’s immune response.

The company’s programs focus on delivering these viruses to tumors, including through its SuperNova platform, which uses engineered allogeneic stem cells. Calidi’s work remains in development, and its products are investigational rather than approved treatments.

AI Generated. May Contain Errors.

Calidi Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

CLDI MarketRank™: 
0.81379861481 of 5 stars

Calidi Biotherapeutics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Calidi Biotherapeutics.

  • Price to Book Value per Share Ratio

    Calidi Biotherapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.33% of the float of Calidi Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Calidi Biotherapeutics has a short interest ratio ("days to cover") of 2.48, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Calidi Biotherapeutics has recently decreased by 17.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Calidi Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Calidi Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Calidi Biotherapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Calidi Biotherapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.30% of the stock of Calidi Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    12.53% of the stock of Calidi Biotherapeutics is held by institutions.

  • Read more about Calidi Biotherapeutics' insider trading history.
Receive CLDI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLDI Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

CLDI Stock Analysis - Frequently Asked Questions

Calidi Biotherapeutics' stock was trading at $18.72 at the start of the year. Since then, CLDI shares have decreased by 96.8% and is now trading at $0.6023.

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) announced its quarterly earnings results on Friday, November, 13th. The company reported ($1.47) EPS for the quarter.

Calidi Biotherapeutics shares reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include NVIDIA (NVDA), KULR Technology Group (KULR), Comstock (LODE), Energy Transfer (ET), Biodexa Pharmaceuticals (BDRX), CrowdStrike (CRWD) and Datavault AI (DVLT).

Company Calendar

Last Earnings
11/13/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:CLDI
Previous Symbol
NYSE:CLDI
CIK
1855485
Fax
N/A
Employees
29
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-368.29%
Return on Assets
-176.58%

Debt

Debt-to-Equity Ratio
0.24
Current Ratio
1.68
Quick Ratio
1.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.33 per share
Price / Book
0.07

Miscellaneous

Outstanding Shares
2,660,000
Free Float
2,546,000
Market Cap
$1.60 million
Optionable
N/A
Beta
1.37

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSEAMERICAN:CLDI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners